Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 142

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 142
---
 as more fully described in the section titled “Description of Capital Stock—Warrants—Class A Warrants;” |

| • |     | 882,948 shares of our common stock issuable upon the exercise of Class B common stock warrants outstanding                                                              
 as of June 30, 2025, with an exercise price of $0.01 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Class B Warrants;” |

| • |     | 1,528,632 shares of our common stock issuable to Maxim Partners LLC upon the exercise of common stock warrants                                                                    
 outstanding as of June 30, 2025, with an exercise price of $0.01 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Maxim Warrants;” |

| • |     | 71,761 shares of our common stock issuable upon the exercise of Series B-1 common stock warrants outstanding as                                                         
 of June 30, 2025, with an exercise price of $0.01 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Series B-1 Warrants;” |

| • |     | 98,456 shares of our common stock issuable upon the exercise of New Series B common stock warrants outstanding as                                                         
 of June 30, 2025, with an exercise price of $1.50 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—New Series B Warrants;” |

| • |     | shares of common stock reserved for future issuance under our 2025 Plan, which became                                                                                                                                                                     
 effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2025 Plan, as more fully described in 
 the section titled “Executive Compensation—Equity Benefit Plans;” and                                                                                                                                                                                     |

| • |     | shares of common stock reserved for future issuance under our ESPP, which became                                                                                                                                                                         
 effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for future issuance under our ESPP, as more fully described 
 in the section titled “Executive Compensation—Equity Benefit Plans.”                                                                                                                                                                                     |

93

MANAGEMENT’S DISCUSSION AND